203 related articles for article (PubMed ID: 11313805)
1. Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial.
Mulvihill S; Warren R; Venook A; Adler A; Randlev B; Heise C; Kirn D
Gene Ther; 2001 Feb; 8(4):308-15. PubMed ID: 11313805
[TBL] [Abstract][Full Text] [Related]
2. Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial.
Nemunaitis J; Ganly I; Khuri F; Arseneau J; Kuhn J; McCarty T; Landers S; Maples P; Romel L; Randlev B; Reid T; Kaye S; Kirn D
Cancer Res; 2000 Nov; 60(22):6359-66. PubMed ID: 11103798
[TBL] [Abstract][Full Text] [Related]
3. A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer.
Ganly I; Kirn D; Eckhardt G; Rodriguez GI; Soutar DS; Otto R; Robertson AG; Park O; Gulley ML; Heise C; Von Hoff DD; Kaye SB
Clin Cancer Res; 2000 Mar; 6(3):798-806. PubMed ID: 10741699
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of a replication-selective adenovirus against ovarian carcinomatosis is dependent on tumor burden, viral replication and p53 status.
Heise C; Ganly I; Kim YT; Sampson-Johannes A; Brown R; Kirn D
Gene Ther; 2000 Nov; 7(22):1925-9. PubMed ID: 11127580
[TBL] [Abstract][Full Text] [Related]
5. Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity.
Nemunaitis J; Cunningham C; Buchanan A; Blackburn A; Edelman G; Maples P; Netto G; Tong A; Randlev B; Olson S; Kirn D
Gene Ther; 2001 May; 8(10):746-59. PubMed ID: 11420638
[TBL] [Abstract][Full Text] [Related]
6. Oncolytic activity of the E1B-55 kDa-deleted adenovirus ONYX-015 is independent of cellular p53 status in human malignant glioma xenografts.
Geoerger B; Grill J; Opolon P; Morizet J; Aubert G; Terrier-Lacombe MJ; Bressac De-Paillerets B; Barrois M; Feunteun J; Kirn DH; Vassal G
Cancer Res; 2002 Feb; 62(3):764-72. PubMed ID: 11830531
[TBL] [Abstract][Full Text] [Related]
7. Clinical trial of E1B-deleted adenovirus (dl1520) gene therapy for hepatocellular carcinoma.
Habib N; Salama H; Abd El Latif Abu Median A; Isac Anis I; Abd Al Aziz RA; Sarraf C; Mitry R; Havlik R; Seth P; Hartwigsen J; Bhushan R; Nicholls J; Jensen S
Cancer Gene Ther; 2002 Mar; 9(3):254-9. PubMed ID: 11896441
[TBL] [Abstract][Full Text] [Related]
8. Functional interactions of antiapoptotic proteins and tumor necrosis factor in the context of a replication-competent adenovirus.
Liu TC; Wang Y; Hallden G; Brooks G; Francis J; Lemoine NR; Kirn D
Gene Ther; 2005 Sep; 12(17):1333-46. PubMed ID: 15920462
[TBL] [Abstract][Full Text] [Related]
9. Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned?
Kirn D
Gene Ther; 2001 Jan; 8(2):89-98. PubMed ID: 11313778
[TBL] [Abstract][Full Text] [Related]
10. [Phase III randomized clinical trial of intratumoral injection of E1B gene-deleted adenovirus (H101) combined with cisplatin-based chemotherapy in treating squamous cell cancer of head and neck or esophagus].
Xia ZJ; Chang JH; Zhang L; Jiang WQ; Guan ZZ; Liu JW; Zhang Y; Hu XH; Wu GH; Wang HQ; Chen ZC; Chen JC; Zhou QH; Lu JW; Fan QX; Huang JJ; Zheng X
Ai Zheng; 2004 Dec; 23(12):1666-70. PubMed ID: 15601557
[TBL] [Abstract][Full Text] [Related]
11. Replication and cytolysis of an E1B-attenuated adenovirus in drug-resistant ovarian tumour cells is associated with reduced apoptosis.
Ganly I; Kim YT; Hann B; Balmain A; Brown R
Gene Ther; 2001 Mar; 8(5):369-75. PubMed ID: 11313813
[TBL] [Abstract][Full Text] [Related]
12. p53 selective and nonselective replication of an E1B-deleted adenovirus in hepatocellular carcinoma.
Vollmer CM; Ribas A; Butterfield LH; Dissette VB; Andrews KJ; Eilber FC; Montejo LD; Chen AY; Hu B; Glaspy JA; McBride WH; Economou JS
Cancer Res; 1999 Sep; 59(17):4369-74. PubMed ID: 10485485
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of a replication-competent adenovirus (ONYX-015) following intratumoral injection: intratumoral spread and distribution effects.
Heise CC; Williams A; Olesch J; Kirn DH
Cancer Gene Ther; 1999; 6(6):499-504. PubMed ID: 10608346
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of E1B gene-attenuated replicating adenoviruses for cancer gene therapy.
Kim J; Cho JY; Kim JH; Jung KC; Yun CO
Cancer Gene Ther; 2002 Sep; 9(9):725-36. PubMed ID: 12189522
[TBL] [Abstract][Full Text] [Related]
15. a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer.
Khuri FR; Nemunaitis J; Ganly I; Arseneau J; Tannock IF; Romel L; Gore M; Ironside J; MacDougall RH; Heise C; Randlev B; Gillenwater AM; Bruso P; Kaye SB; Hong WK; Kirn DH
Nat Med; 2000 Aug; 6(8):879-85. PubMed ID: 10932224
[TBL] [Abstract][Full Text] [Related]
16. [Safety of an E1B deleted adenovirus administered intratumorally to patients with cancer].
Yuan ZY; Zhang L; Li S; Qian XZ; Guan ZZ
Ai Zheng; 2003 Mar; 22(3):310-3. PubMed ID: 12654194
[TBL] [Abstract][Full Text] [Related]
17. A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma.
Hecht JR; Bedford R; Abbruzzese JL; Lahoti S; Reid TR; Soetikno RM; Kirn DH; Freeman SM
Clin Cancer Res; 2003 Feb; 9(2):555-61. PubMed ID: 12576418
[TBL] [Abstract][Full Text] [Related]
18. Adenovector-mediated gene delivery of interleukin-2 in metastatic breast cancer and melanoma: results of a phase 1 clinical trial.
Stewart AK; Lassam NJ; Quirt IC; Bailey DJ; Rotstein LE; Krajden M; Dessureault S; Gallinger S; Cappe D; Wan Y; Addison CL; Moen RC; Gauldie J; Graham FL
Gene Ther; 1999 Mar; 6(3):350-63. PubMed ID: 10435085
[TBL] [Abstract][Full Text] [Related]
19. Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer.
Vasey PA; Shulman LN; Campos S; Davis J; Gore M; Johnston S; Kirn DH; O'Neill V; Siddiqui N; Seiden MV; Kaye SB
J Clin Oncol; 2002 Mar; 20(6):1562-9. PubMed ID: 11896105
[TBL] [Abstract][Full Text] [Related]
20. A phase I study of Adp53 (INGN 201; ADVEXIN) for patients with platinum- and paclitaxel-resistant epithelial ovarian cancer.
Wolf JK; Bodurka DC; Gano JB; Deavers M; Ramondetta L; Ramirez PT; Levenback C; Gershenson DM
Gynecol Oncol; 2004 Aug; 94(2):442-8. PubMed ID: 15297186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
